期刊文献+

孕烷X受体:肝脏疾病的潜在药物靶标 被引量:4

Pregnane X Receptor: a Potential Therapeutic Target for Liver Diseases
原文传递
导出
摘要 孕烷X受体(PXR)属于配体依赖性调控靶基因的核受体亚家族,激活后可调控多种药物代谢酶和转运体的表达,影响临床药物的疗效和耐药性。PXR通过调控肝脏中脂质和糖类物质的代谢,影响肝脏疾病的发生发展进程,可作为肝脏疾病药物筛选与疾病治疗的潜在药物靶标。深入了解PXR及其调控机制对于预测药物-药物相互作用、避免或减轻药物不良反应以及设计和研发以PXR为靶点的新型药物均具有十分重要的意义。对PXR在肝脏疾病中的调控作用及药物通过PXR干预肝脏疾病进程的研究进展进行概述。 Pregnane X receptor(PXR), a member of the nuclear receptor subfamily of ligand-dependent regulatory target genes, regulates the expression of multiple drug metabolizing enzymes and transporters upon activation, thus affecting the efficacy and drug resistance of clinical medicines. PXR is involved in the pathogenesis and development liver diseases by regulating the metabolism of lipids and carbohydrates in the liver, emerging as a potential drug target for drug screening and treatment of liver diseases. The deep understanding of PXR and its regulatory mechanisms has great significance for predicting drug-drug interactions, avoiding or mitigating adverse drug reactions, designing and developing novel drugs targeting PXR. This article summarized the regulatory roles of PXR in liver diseases and the research progress in drug intervention for liver disease progression through PXR.
作者 辛瑜 杨暄 奚涛 熊晶 XIN Yu;YANG Xuan;XI Tao;XIONG Jing(School of Life Science and Technology,China Pharmaceutical University,Nanjing 210009,China;Department of Pharmacology,Nanjing Medical University,Nanjing 210029,China)
出处 《药学进展》 CAS 2018年第12期922-928,共7页 Progress in Pharmaceutical Sciences
基金 国家自然科学基金(No.81302855) 江苏省自然科学基金(No.BK2012446)
关键词 孕烷X受体 药物研发 药物代谢 肝脏疾病 pregnane X receptor drug development drug metabolism liver disease
  • 相关文献

参考文献2

二级参考文献11

  • 1Meetings[J].World Journal of Gastroenterology,2010,16(4). 被引量:13
  • 2Joachim Lupberger,Eberhard Hildt.Hepatitis B virus-induced oncogenesis[J].World Journal of Gastroenterology,2007,13(1):74-81. 被引量:57
  • 3Beasley RP;Hwang LY;Lin CC;Chien CS.Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan,1981.
  • 4Liaw YF;Sung JJ;Chow WC.Lamivudine for patients with chronic hepatitis B and advanced liver disease,2004.
  • 5El-Serag HB.Hepatocellular carcinomaThe New England Journal of Medicine,2011.
  • 6Hoofnagle JH,Doo E,Liang TJ,et al.Management of hepatitis B: summary of a clinical research workshopHepatology,2007.
  • 7Turati F,Edefonti V,Talamini R,Ferraroni M,MalvezziM,Bravi F,Franceschi S,Montella M,Polesel J,ZucchettoA,La Vecchia C,Negri E,Decarli A.Family history of livercancer and hepatocellular carcinoma. Hepatology . 2012
  • 8Scott L. Friedman.Mechanisms of Hepatic Fibrogenesis[J]. Gastroenterology . 2008 (6)
  • 9Herve, Mommeja-Marin,Elsa Mondou,M.Robert Blum,Franck Rousseau.Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: Analysis and review of the literature[J]. Hepatology . 2003 (6)
  • 10Giovanna Fattovich,Tommaso Stroffolini,Irene Zagni,Francesco Donato.Hepatocellular carcinoma in cirrhosis: Incidence and risk factors[J]. Gastroenterology . 2004 (5)

共引文献12

同被引文献40

引证文献4

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部